Form D · Biotechnology
Alida Biosciences Inc.
San Diego, CA · CIK 0001870548
Offering snapshot reported Jun 17, 2024 · SEC filing
- Reported sold
- $7.52M Offering amount: $8.52M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 7, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2024 | Initial | $7,520,384 | No comparison | 3 | SEC filing |
| May 23, 2022 | Initial | $3,999,999 | No comparison | 2 | SEC filing |
| Jul 2, 2021 | Initial | $510,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516210
The total offering amount includes $1,020,384 on convertible securities. The total offering amount includes $3,750,000 committed to the issuer in future tranche closings.
Source: Form D, filed Jun 17, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Conley | Director |
| John Drewry | Director |
| Landon Merrill | Director |
| Gudrun Stengel | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
14813 Priscilla Street
San Diego, CA, 92129
San Diego, CA, 92129